← Back to Clinical Trials
Recruiting NCT06960096

NCT06960096 Cognitive Decline Following Deep Brain Stimulation: A DBS-fMRI Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06960096
Status Recruiting
Phase
Sponsor Medical University of South Carolina
Condition Deep Brain Stimulation
Study Type OBSERVATIONAL
Enrollment 55 participants
Start Date 2025-08-21
Primary Completion 2028-04-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
DBS combined with fMRI

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 55 participants in total. It began in 2025-08-21 with a primary completion date of 2028-04-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The objective of this research study is to understand how Deep Brain Stimulation (DBS) targeting the subthalamic nucleus (STN) affects cognitive networks in the brain, potentially leading to cognitive decline in patients with Parkinson's Disease (PD). A total of 55 participants with PD who have undergone DBS surgery will be recruited from MUSC's Clinical DBS Program. Participants will attend two post-DBS visits: a 3-hour visit for consent, demographic, and cognitive assessments, and a 3-hour DBS-MRI visit to evaluate brain network connectivity with stimulation ON and OFF. These findings will help improve patient selection for surgery and optimize the selection of stimulation targets that minimize undesirable cognitive side effects.

Eligibility Criteria

Inclusion Criteria: * Subjects above 18 years of age * Individuals with a PD diagnosis as defined by the UK Brain Bank diagnostic criteria for Parkinson's disease (58) which have undergone a neurological and neuropsychological evaluation at MUSCs movement disorder center, and were selected to undergo 3T compatible unilateral or bilateral STN- DBS implants Exclusion Criteria: * Uncorrected visual or hearing impairments, as indicated by self-report * Individuals who are pregnant or expect to become pregnant during the course of the study * Individuals that have a history of neurological disease (other than PD) including previous stroke, major head trauma, and epilepsy or seizures. * Individuals with claustrophobia, or the inability to lie supine position in the MRI scanner * COPD with oxygen dependence * Non-MRI compatible metal implants (surgical clips or staples, cardiac pacemakers etc.)

Contact & Investigator

Central Contact

Recruitment Coordinator

✉ malakout@musc.edu

📞 843-792-0235

Principal Investigator

Daniel Lench, PhD

PRINCIPAL INVESTIGATOR

Medical University of South Carolina

Frequently Asked Questions

Who can join the NCT06960096 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Deep Brain Stimulation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06960096 currently recruiting?

Yes, NCT06960096 is actively recruiting participants. Contact the research team at malakout@musc.edu for enrollment information.

Where is the NCT06960096 trial being conducted?

This trial is being conducted at Charleston, United States.

Who is sponsoring the NCT06960096 clinical trial?

NCT06960096 is sponsored by Medical University of South Carolina. The principal investigator is Daniel Lench, PhD at Medical University of South Carolina. The trial plans to enroll 55 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology